Symptomatic Benign Prostatic Hyperplasia (BPH) is a common condition in middle aged and elderly men.
BPH is a chronic disease which is characterised by the presence of several urinary symptoms that can be related to bladder emptying (voiding or obstructive symptoms) or filling (storage or irritative symptoms). Typical voiding symptoms are slow stream, hesitancy and intermittency. Typical storage symptoms are increased daytime frequency, nocturia and urgency. Nocturia, i. e. awakening one or more times at night for voiding, reduces the patient's quality of sleep and has a significant negative impact on how the patient feels the next day in terms of energy level/fatigue, concentration and mood and ultimately overall well-being and quality of life.
Pharmacological therapy is the cornerstone of BPH treatment
Pharmacological therapy, in particular alpha-1 receptor antagonists, is the cornerstone of initial treatment for this condition, to relieve bothersome symptoms, to reduce the static and/or dynamic component of obstruction and to improve the quality of life.
Products
Flomax®, Alna®, Josir®, Pradif®, Secotex®, Urolosin®, Mecir® (tamsulosin) Indicated for the treatment of Lower urinary tract Symptoms (LUTS) associated with benign prostate hyperplasia and available since 1996 as capsule controlled release formulation in the main world markets.
Starting in 2005, a new tablet formulation based on the OCAS® (Oral Controlled Absorption System) technology has been made available in many European markets and in Canada. Flomax® CR, Alna® OCAS, Pradif® T , Urolosin® OCAS .
Disclaimer:
We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.
Therefore please check the registration details of this/these product(s) locally in order to get up-to-date information.
